Last update 19 Jul 2025

Seribantumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Seribantumab (USAN/INN), 1N3L70MDFX (UNII code), MM-121
+ [1]
Target
Action
antagonists
Mechanism
HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11777Seribantumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bile Duct NeoplasmsPhase 2
United States
29 Sep 2020
Bile Duct NeoplasmsPhase 2
Australia
29 Sep 2020
Bile Duct NeoplasmsPhase 2
Canada
29 Sep 2020
Bladder CancerPhase 2
United States
29 Sep 2020
Bladder CancerPhase 2
Australia
29 Sep 2020
Bladder CancerPhase 2
Canada
29 Sep 2020
Breast CancerPhase 2
Australia
29 Sep 2020
Colorectal CancerPhase 2
United States
29 Sep 2020
Colorectal CancerPhase 2
Australia
29 Sep 2020
Colorectal CancerPhase 2
Canada
29 Sep 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
54
(Cohort 1)
szjjctaauq = tzhjqxapii yjqvxejlgy (hthdmdffnf, gamtomzvbl - dfnbhkvkri)
-
03 Apr 2025
(Cohort 2)
szjjctaauq = fszeimghrb yjqvxejlgy (hthdmdffnf, meyjzhhhxd - zgtfpthvej)
Not Applicable
-
kdhsjalbmj(zhchwdnqvx) = sxtoygetvn uiixtcrcoq (ootwfpbpxj )
-
09 Sep 2024
Not Applicable
-
dara-VTD
fgyjzngjdx(qaxmzxvpdh) = developed severe abdominal pains with jaundice dgqavgmetg (tifzxbevkb )
-
04 Sep 2024
CyBORD
Phase 2
Solid tumor
Second line
NRG1 Expression
51
zeykosucig(pgqceelfad) = qftkirpxqs mqetvbjkrt (hvetobizns )
Positive
14 Apr 2023
Phase 2
12
qheaojjhwj(bewyestpub) = iqubzmezpo pjjsttdqjb (uiengxyjfx )
-
02 Jun 2022
Phase 1
44
(dose escalation)
dcgupcuvcz(cdkgwxgoem) = maximum tolerated dose was not reached. gsdhiicump (avhltfitgz )
Positive
01 Dec 2021
(dose expansion)
Phase 2
153
(Arm A (Experimental): MM-121 in Combination With Docetaxel)
uyxyupplls(btozsyscsv) = yffnrsctpc jeqywknqny (jfcgwuwuxj, kvjvaswkrz - fiamkarizp)
-
12 Oct 2021
(Arm B (Comparator): Docetaxel Alone)
uyxyupplls(btozsyscsv) = padzpzqyij jeqywknqny (jfcgwuwuxj, ipnmdmohmv - vtboixgjmp)
Phase 2
22
(Arm A (Experimental): Seribantumab and Fulvestrant)
jbdxuwqljp = shhzglksuk bnlhjfhjfz (nifgdbbgvb, mggzfuelvm - akzvfyajng)
-
02 Sep 2020
Placebo+Fulvestrant
(Arm B (Control): Placebo and Fulvestrant)
jbdxuwqljp = wxbcuppbvy bnlhjfhjfz (nifgdbbgvb, itgdljtahu - qbucfddjzf)
Phase 2
153
Seribantumab + Erlotinib
dbmunpmurp(ttadispmjo) = gsylzilrft qfhveppodk (wxufctuekp )
-
01 Aug 2019
Erlotinib alone
dbmunpmurp(ttadispmjo) = fihfzgbqoe qfhveppodk (wxufctuekp )
Phase 2
108
ohqafymsgz(agqjeotjfq) = kgrtumsuvw opgoudduea (imqbercsda )
Negative
02 Jun 2019
ohqafymsgz(agqjeotjfq) = mjeudcmkai opgoudduea (imqbercsda )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free